The injection looked clean. The client felt fine. Forty minutes later, on the drive home, she messaged you a photo. The skin around her left ala has gone a strange dusky grey, and there is a pain she cannot quite locate.
This is the moment every injector trains for. It is also the moment most injectors freeze, because the textbook recognition signs are subtle in the early phase, the client is no longer in the chair, and the protocol you read about in training feels different when it is your client and your reputation.
This post is the recognition framework I teach. It is not the full treatment protocol, that is a hands-on module inside the RAG Pathway. It is the ninety-minute clinical thinking that decides whether the next steps land calmly and quickly, or whether you waste the window.
What vascular occlusion actually is
Vascular occlusion happens when filler material enters or compresses a blood vessel. The downstream tissue stops getting arterial supply, venous drainage, or both. Once perfusion is interrupted, the tissue starts to die.
There are two mechanisms, and they matter because the recognition signs differ.
Arterial occlusion is the worse one. Filler is injected into or directly compresses an artery. Distal tissue loses oxygenated blood. Recognition is fast: blanching within minutes, a livedo reticularis pattern (a fishnet mottling of pale and purple), severe pain disproportionate to the injection itself, and skin that is cold to the touch. The peer-reviewed literature on this is well-established, with DeLorenzi's 2014 paper in the Aesthetic Surgery Journal still the most-cited clinical reference.
Venous occlusion is slower and easier to miss. Filler compresses or enters a vein. Drainage backs up. The tissue goes a dusky purple-grey colour, swelling builds, and pain develops over hours rather than minutes. It can convert into full vascular compromise if untreated, but the recognition timeline is longer and the signs less dramatic. This is the one that gets missed by injectors who only learned the arterial recognition pattern.
A third pattern, embolic occlusion, is the rare and serious one. Filler travels distally through a vessel and lodges where it can do the most damage. The most-feared example is retrograde travel up the supratrochlear or dorsal nasal artery into the ophthalmic system, with vision loss as the result. Goodman and colleagues' 2020 consensus paper in Plastic and Reconstructive Surgery Global Open is the standard reference for this and remains the document I send practitioners who want the international consensus.
The recognition signs, ranked by reliability
I teach this as a hierarchy because the early phase of vascular compromise is the part everyone gets wrong.
-
Blanching is the most reliable early sign. The skin in the supplied territory goes white as arterial flow stops. It can be patchy, follow a vascular distribution, or be diffuse. If you blanch a treated area and it does not refill within a couple of seconds, treat that as occlusion until proven otherwise.
-
Livedo reticularis is the pathognomonic mid-phase sign. The fishnet purple-and-pale mottling is unmistakable once you have seen it, and it tells you the dermal microcirculation is failing. If you see livedo, the window is closing.
-
Pain disproportionate to the procedure is the most under-recognised sign. A client who reports severe, throbbing, unrelenting pain after a routine filler treatment is telling you something is wrong even if the skin still looks reasonable. Take this seriously every time.
-
Capillary refill is your bedside diagnostic. Press the suspected territory firmly for two seconds, release, and watch. Refill should be under two seconds. Slower than that, or absent, means perfusion is impaired.
-
Skin temperature is a confirmation rather than a screening sign. Cold to the touch in a treated area is a late sign, not an early one. Do not rely on it to make the call.
-
Dusky grey or purple skin is the venous-pattern late sign and a major red flag.
-
Visual symptoms (any visual change, blurring, scotoma, pain behind the eye) need same-day specialist ophthalmology assessment. This is an emergency, not a wait-and-see. The ACE Group UK guidance and the international consensus are both unambiguous on this.
The mistake injectors make is waiting for two or three signs to coincide before acting. By that point you have spent the window. The right threshold is one strong sign or two soft signs. That is the moment to start the response, not five minutes later.
The ninety-minute window
The reason the early window matters is hyaluronidase. For hyaluronic acid fillers, hyaluronidase dissolves the offending material and reopens the vessel. The published clinical experience consistently supports flooding the affected territory generously and early, with repeat dosing as needed.
The window is not a hard cliff at ninety minutes. Tissue salvage has been documented later. But the literature is also consistent that earlier is better, and that the practitioners who lose tissue are almost always the ones who waited, not the ones who acted.
This is why my own protocol, taught inside the RAG Pathway, is built around recognition speed rather than treatment elegance. The right hyaluronidase, the right volume, the right repeat schedule, are all in the literature. What is harder to teach, and what kills tissue when it is missing, is the willingness to start treatment on a clinical suspicion before you are certain.
If you find yourself thinking "I'm not sure but I'd better start hyase", you are doing it right. If you find yourself thinking "I'll wait twenty minutes and see if it gets worse", you are doing it wrong.
What sits inside your scope, and what does not
Hyaluronidase administration for skin and soft-tissue VO is within the scope of trained injectors who hold the appropriate prescribing or supply route. The detail of who can prescribe what, in which setting, under which standing order or PGD, is jurisdictionally specific. The JCCP standards are the cleanest UK reference for the supervisory and prescribing structure required.
What is not within most aesthetic practitioners' scope:
- Any vision symptom. Same-day ophthalmology referral. Blue Light if needed. The window for sight loss is much shorter than for skin.
- Central facial necrosis with systemic signs. A&E, immediately.
- Non-HA fillers (calcium hydroxylapatite, poly-L-lactic acid, polymethyl methacrylate). Hyaluronidase does not dissolve them. The intervention pathway is different, and most aesthetic practitioners do not stock the necessary products. Refer.
A confident, fast referral is not a failure. It is the standard of care.
Why prevention is the longer conversation
Recognising VO matters. Not having to recognise it matters more. The prevention literature is denser than the treatment literature, and the practical points that move the needle in clinic are:
- Aspiration before injection. The literature is mixed on its sensitivity, but the pre-test probability of catching an intravascular needle goes up when you aspirate, hold, and watch. Aspiration is not a guarantee, but it is a layer.
- Cannula over needle in high-risk territories. The peri-orbital, peri-nasal, glabellar, and forehead regions are the high-incidence zones for serious VO. Blunt cannulas reduce risk. They do not eliminate it.
- Anatomy before product. Knowing where the supratrochlear, dorsal nasal, angular, and facial arteries actually run on this client, on this anatomy, in this lighting, beats every safety device. The injectors who do not have VO incidents are the ones who slow down before the injection, not the ones who move fast and clean up after.
- Slow injection, low volume per pass, retrograde technique. All in the literature. All worth doing every single time.
Why this matters for your reputation
This is the part most injectors do not want to hear. A vascular occlusion handled transparently, treated quickly, and disclosed honestly to the client is recoverable. A vascular occlusion that the practitioner tries to hide, downplays, or delays referral on, is the kind of incident that ends careers, drives complaints to the JCCP and the regulator, and makes the local headlines.
The injectors I have watched come through a serious complication intact are the ones who said, in real time, "I'm worried this might be a vascular event, here's what we're doing right now, here's what I need you to do, and here is the consultant I'm referring you to as a precaution." The injectors who lost their reputations said, in real time, "It looks fine, take a paracetamol, message me tomorrow."
The recognition window is also a transparency window. Use both.
What to keep on hand, today
- A vascular occlusion crash kit with hyaluronidase in date, sterile water, syringes, needles, and the protocol on a laminated card.
- The phone number for the nearest A&E and the nearest emergency ophthalmology service.
- A written referral pathway you have read through at least once in the last six months.
- Your indemnity insurance contact. They want to know about a serious AE in real time, not after a complaint.
- A clinical photography setup that can capture the affected territory in good light.
If any of those is missing today, fix that before your next injection list.
Continue your reading
The full recognition-and-response framework, including the ACE Group protocol, the photography template, the supervisor and indemnity contact log, and the post-event debrief script, sits inside the RAG Pathway, the four-week regulatory and clinical-safety programme. The wider regulatory context lives at UK aesthetics regulation, decoded, and the regulator-by-regulator standards we teach against are at the eight UK regulators.
Bernadette Tobin is a Registered Nurse and Independent Nurse Prescriber with an MSc in Advanced Practice (Level 7). She is the founder of Aesthetics Unlocked and a 2026 Educator of the Year Nominee at the Beauty & Aesthetics Awards. She runs Visage Aesthetics in Essex, named Best Non-Surgical Aesthetics Clinic 2026 by the Health, Beauty & Wellness Awards. Verifiable on the NMC public register.